News
FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'
Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
Sunday 4 October 2026
